

Product Name: EUK 134 Revision Date: 01/10/2021 Product Data Sheet

CI

DE

EUK 134

Cat. No.:	B1325
CAS No.:	81065-76-1
Formula:	C18H18CIMnN2O4
M.Wt:	416.74
Synonyms:	
Target:	Neuroscience
Pathway:	Amyloid β
Storage:	Store at -20°C
	210

Solvent & Solubility

	≥2.11 mg/mL in H20	≥2.11 mg/mL in H2O; ≥20.85 mg/mL in DMSO; ≥3.24 mg/mL in EtOH			
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg
		1 mM	2.3996 mL	11.9979 mL	23.9958 mL
		5 mM	0.4799 mL	2.3996 mL	4.7992 mL
		10 mM	0.2400 mL	1.1998 mL	2.3996 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Salen-manganese complexes;SOD mimetic

IC₅₀ & Target

In Vitro

Cell Viability Assay	and the second
Cell Line:	Human dermal fibroblasts
Preparation method:	The solubility of this compound in DMSO is >20.9mg/mL. General tips for
	obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes
	and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
	below -20°C for several months.
Reacting conditions:	0, 20, 40, 60 and 80 μM, 18h

1 | www.apexbt.com

	Applications:	In human dermal fibroblasts, EUK-134 had significantly greater cytoprotective	
		activity than did EUK-8. EUK-134 (80 $\mu\text{M})$ was equally as protective as 290	
		units/ml of bovine liver catalase.	
	Animal experiment		
	Animal models:	male Sprague-Dawley rats with middle cerebral artery occlusion (MCA-o)	
	Dosage form:	0.25 and 2.5 mg/kg, diluted in 0.9% saline, single intravenous bolus injection at	
	DE	3 hr after MCA-o, killed at 21 hr or 72 hr.	
	Applications:	In male Sprague-Dawley rats with middle cerebral artery occlusion (MCA-o),	
		EUK-134 significantly lowered infarct volumes compared with those of	
In Vivo		vehicle-injected rats. EUK-134 at 2.5 mg/kg reduced the infarct volume by	
		~90%. After 72 hr, the EUK-134-treated group still exhibited a substantial	
		degree of protection and the mean infarct volume did not differ significantly	
		from that at 21 hr.	
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may	
	810	slightly differ with the theoretical value. This is caused by an experime	
	DE	system error and it is normal.	

Product Citations

See more customer validations on www.apexbt.com.

References



PET

[1]. Baker K, Marcus C B, Huffman K, et al. Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury[J]. Journal of Pharmacology and Experimental Therapeutics, 1998, 284(1): 215-221.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.













